OakChart

Xeris Biopharma Holdings Inc

XERSHealthcare·Drug Manufacturers - Specialty & Generic·USA·Mid·NASD·Nov 11 • 3:59 PM ET

16.52+0.69 (4.36%)
2026-11-12 06:24 CET
Market cap
3,018.20 USD m
Revenue, TTM
368.26 USD m
Net income, TTM
-6.50 USD m
Free cash flow, TTM
72.62 USD m
EPS diluted, TTM
-0.05
P/E
-
Compare

Price

XERS against its 20, 50 and 200-day averages
2050200beatmiss
7.5010.0012.5015.009.7M19.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26XERSclose 16.5220-day 11.7350-day 10.08200-day 7.7416.5252w low

0.3% under the 52-week high of 16.57 on 11 Nov 2026. 52-week low 5.25 on 24 Mar 2026. Last 15 sessions, 64.7% high to low

Volume 1.40× normal · the line is the 50-bar volume average

Profile

XERS
52-week range, 100% of the way up
5.2516.11

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

IndexRUT
Employees435
IPOJun 21, 2018
Beta0.77
ATR, 14d0.80
Rel volume1.40
Short float5.18%
Insider own5.05%
Inst own61.11%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap3.02B
Enterprise Value3.11B
Income-6.50M
Sales368.26M
Book/sh0.27
Cash/sh0.72
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees435
IPOJun 21, 2018

Ratios

P/E-
Forward P/E39.33
PEG-
P/S8.20
P/B61.82
P/C23.03
P/FCF41.56
EV/EBITDA52.22
EV/Sales8.45
Quick Ratio1.58
Current Ratio2.15
Debt/Eq4.63
LT Debt/Eq4.50
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.05
EPS next Y0.42
EPS next Q0.07
EPS this Y-661.27%
EPS next Y2433.33%
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y38.33% 70.20%
EPS Y/Y TTM63.43%
Sales Y/Y TTM38.37%
EPS Q/Q1597.14%
Sales Q/Q44.16%
EarningsNov 05 BMO
EPS/Sales Surpr.89.27% 5.45%

Ownership

Insider Own5.05%
Insider Trans-4.55%
Inst Own61.11%
Inst Trans2.79%
ROA-1.64%
ROE-27.11%
ROIC-2.42%
Gross Margin84.44%
Oper. Margin12.70%
Profit Margin-1.76%
SMA2040.87%
SMA5063.86%
SMA200113.55%
Trades-

Technical

Shs Outstand182.57M
Shs Float173.47M
Short Float5.18%
Short Ratio3.32
Short Interest8.99M
52W High16.11 2.56%
52W Low5.25 214.67%
Volatility7.88% 5.54%
ATR (14)0.80
RSI (14)85.12
Beta0.77
Rel Volume1.40
Avg Volume2.71M
Volume3,793,232

Performance

Perf Week57.93%
Perf Month61.96%
Perf Quarter98.32%
Perf Half Y156.92%
Perf YTD110.45%
Perf Year122.04%
Perf 3Y880.42%
Perf 5Y694.23%
Perf 10Y-
Recom1.38
Target Price17.29
Prev Close15.83
Price16.52
Change %4.36%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Dec 09, 2025InitiatedBBarclaysOverweight$9-45.5%
Aug 12, 2025ResumedHH.C. WainwrightBuy$10-39.5%
Nov 11, 2024DowngradePPiper SandlerOverweight → Neutral$3-81.8%
Mar 28, 2024InitiatedOOppenheimerOutperform$5-69.7%
Aug 28, 2023InitiatedCCraig HallumBuy$4.50-72.8%
Oct 21, 2022InitiatedJJefferiesBuy$4-75.8%
Apr 28, 2022InitiatedCCraig HallumBuy$6.50-60.7%
Nov 17, 2021InitiatedSSVB LeerinkOutperform$6-63.7%
Oct 29, 2021InitiatedHH.C. WainwrightBuy$4-75.8%
Apr 07, 2021ResumedRRBC Capital MktsOutperform$11-33.4%

Peers

Mkt cap
TickerCompanyMkt cap
AMPHAmphastar Pharmaceuticals Inc1.22B
CORTCorcept Therapeutics Inc8.16B
ETONEton Pharmaceuticals Inc1.97B
AMLXAmylyx Pharmaceuticals Inc4.09B
ANIPANI Pharmaceuticals Inc1.63B
SUPNSupernus Inc6.12B
COLLCollegium Pharmaceutical Inc770.99M
RYTMRhythm Pharmaceuticals Inc7.78B
HRMYHarmony Biosciences Holdings Inc2.01B
ASNDAscendis Pharma A/S17.03B

Insider trading

latest 14 of 59
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
McCulloch KevinSee RemarksNov 05 '26Sale12.4925,000312,2151,559,208Nov 06 04:32 PM
KEVIN MCCULLOCHOfficerNov 05 '26Proposed Sale10.4625,000261,500Nov 05 04:31 PM
Pieper StevenSee RemarksNov 02 '26Sale10.235,00051,1741,346,053Nov 04 04:58 PM
Hecht BethSee RemarksNov 02 '26Sale10.2325,000255,8281,086,130Nov 04 04:57 PM
McCulloch KevinSee RemarksNov 02 '26Sale10.2315,000153,4881,584,208Nov 04 04:57 PM
BETH HECHTOfficerNov 02 '26Proposed Sale10.7175,000803,250Nov 02 04:39 PM
Pieper StevenSee RemarksOct 01 '26Sale9.415,00047,0361,351,053Oct 02 04:54 PM
McCulloch KevinSee RemarksOct 01 '26Sale9.4115,000141,1201,599,208Oct 02 04:54 PM
Hecht BethSee RemarksOct 01 '26Sale9.4116,666156,7921,111,130Oct 02 04:54 PM
BETH HECHTOfficerOct 01 '26Proposed Sale9.5616,666159,327Oct 01 04:26 PM
McCulloch KevinSee RemarksSep 28 '26Sale10.0025,000250,0001,614,208Sep 29 04:59 PM
KEVIN MCCULLOCHOfficerSep 28 '26Proposed Sale9.1070,000637,000Sep 28 04:19 PM
McCulloch KevinSee RemarksSep 01 '26Sale8.4915,000127,3081,639,208Sep 01 06:21 PM
Hecht BethSee RemarksSep 01 '26Sale8.4916,666141,4341,127,796Sep 01 06:21 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
VXFVanguard Extended Market Index ETFAUM: 30.47B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
FYCFirst Trust Small Cap Growth AlphaDEX FundAUM: 1.35B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-050.0600.0320.060107.23101.686
2026Q22026-08-06-0.1800.012-0.18092.1090.137
2026Q12026-05-070.010-0.0030.01382.4579.837
2025Q42026-03-020.0600.0210.06285.8182.205
2025Q32025-11-060.0000.0060.00474.0674.196
2025Q22025-08-07-0.010-0.028-0.01271.5464.445
2025Q12025-05-08-0.060-0.050-0.06157.8057.626
2024Q42025-03-06-0.030-0.056-0.03457.0058.106
2024Q32024-11-08-0.110-0.087-0.10652.8651.456
2024Q22024-08-08-0.100-0.097-0.10146.5145.846
2024Q12024-05-09-0.140-0.106-0.13540.2641.815
2023Q42024-03-06-0.100-0.086-0.09742.5143.175
2023Q32023-11-09-0.090-0.105-0.08848.3240.645
2023Q22023-08-08-0.140-0.115-0.14536.8935.164
2023Q12023-05-09-0.120-0.158-0.12332.2730.894
2022Q42023-03-08-0.100-0.149-0.09532.5430.964

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-4.810-4.714-4.8102.721.50
2020FY-2.140-2.140-2.13720.1622.03
2021FY-1.550-1.218-1.55349.2847.47
2022FY-0.700-0.674-0.698109.26107.94
2023FY-0.450-0.389-0.452153.36162.58
2024FY-0.370-0.359-0.374196.64201.08
2025FY0.003-0.0220.003291.85288.22
2026FY--0.018--401.51
2027FY-0.420--526.63
2028FY-0.711--641.35
2029FY-1.017--741.7
2030FY-1.265--896.65

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-05660119.03117.1121.5
2026Q4S2026-10-20610111.02109.4113.5
2026Q4S2026-10-02611111.02109.4113.5
2026Q4S2026-09-20602110.73109.3113.5
2026Q4S2026-09-09612110.73109.3113.5
2026Q4S2026-09-08612110.57109.3112.5
2026Q4S2026-09-05612110.56109.25112.5
2026Q4S2026-08-07622110.56109.25112.5
2026Q4S2026-08-06622110.61109.25112.8
2026Q4S2026-07-21620111.74109.3113.2
2026Q4S2026-07-17642111.74109.3113.2
2026Q4S2026-07-16642111.75109.3113.2
2026Q4S2026-07-07632111.24109.3113.2
2026Q4S2026-06-22632111.14108.7113.2

Estimate history

EPS, annual-1.29-4.988-4.81-2.137-1.553-0.698-0.452-0.3740.003-0.0464
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.106-0.034-0.061-0.0120.0040.0620.013-0.180.059
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1.5562.4232.72220.43549.59110.248163.914203.07291.845368.26
Period201720182019202020212022202320242025TTM
Sales, quarterly54.26860.09960.11971.53974.3885.80783.12792.1107.225
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual20.59120.80827.21559.611124.873136.273138.131149.429166.215182.568
Period201720182019202020212022202320242025MRQ
Shares, quarterly149.004149.429156.014161.225165.528166.215172.559173.592182.568
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue368.26291.85203.07163.91110.2549.5920.432.722.42
Cost of Goods Sold Incl. D&A57.3053.4147.6739.4933.4813.679.232.680.32
Gross Profit310.95238.43155.40124.4376.7735.9211.210.042.10
Selling, General and Administrative Excl. Other264.17213.54189.04168.44157.22141.3893.05122.4261.45
Research and Development38.3831.1625.5622.3420.9725.0619.9260.4440.65
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income46.7824.90-33.65-44.01-80.45-105.46-81.85-122.38-59.34
Interest Expense27.4429.0833.1726.6114.107.187.367.162.54
Unusual Expense30.780.00-4.40-2.364.1110.406.51-0.69-0.20
Net Income Before Taxes-6.500.55-57.10-63.50-96.08-122.72-91.25-126.04-60.08
Income Taxes0.000.00-2.27-1.25-1.420.00-0.11-0.460.00
Consolidated Net Income-6.500.55-54.84-62.26-94.66-122.72-91.14-125.58-60.08
Net Income From Continuing Operations-6.500.55-54.84-62.26-94.66-122.72-91.14-125.58-60.08
Net Income-6.500.55-54.84-62.26-94.66-122.72-91.14-125.58-60.08
EPS (Recurring)0.080.00-0.39-0.46-0.68-1.46-2.03-4.83-5.00
EPS (Basic, Before Extraordinaries)-0.040.00-0.37-0.45-0.70-1.55-2.14-4.81-4.99
EPS (Diluted)-0.050.00-0.37-0.45-0.70-1.55-2.14-4.81-4.99
EBITDA59.6237.59-21.02-30.85-67.78-103.58-80.38-121.30-59.02
Non-Operating Income (Expense)4.954.745.324.752.580.314.462.811.61
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense31.2822.3714.518.479.6111.386.044.731.73
Price To Sales Ratio4.934.652.451.971.644.6710.2767.6384.52
Gross Margin84.4481.7076.5275.9169.6372.4454.841.5186.79
Operating Margin12.708.53-16.57-26.85-72.97-212.66-400.52-4,495.96-2,449.20
Net Margin-1.760.19-27.00-37.98-85.86-247.48-446.00-4,613.52-2,479.57
Shares Outstanding182.57166.22149.43138.13136.27124.8759.6127.2120.81
Market Capitalization3,018.203,018.20505.38324.59180.86365.40240.96190.31354.74

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue107.2292.1083.1385.8174.3871.5460.1260.10
Cost of Goods Sold Incl. D&A15.1415.2213.2813.6613.7114.6111.4412.19
Gross Profit92.0876.8869.8472.1560.6756.9348.6847.91
Selling, General and Administrative Excl. Other75.1771.7061.9355.3853.9452.4551.7746.23
Research and Development11.0610.678.787.877.488.057.756.09
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income16.925.177.9216.776.734.48-3.091.68
Interest Expense6.466.956.887.157.277.367.307.70
Unusual Expense0.0030.780.000.000.000.000.00-0.00
Net Income Before Taxes11.29-31.102.2311.080.62-1.93-9.22-5.11
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income11.29-31.102.2311.080.62-1.93-9.22-5.11
Net Income From Continuing Operations11.29-31.102.2311.080.62-1.93-9.22-5.11
Net Income11.29-31.102.2311.080.62-1.93-9.22-5.11
EPS (Recurring)0.06-0.060.010.060.00-0.01-0.06-0.03
EPS (Basic, Before Extraordinaries)0.06-0.180.010.070.00-0.01-0.06-0.03
EPS (Diluted)0.06-0.180.010.060.00-0.01-0.06-0.03
EBITDA20.148.3811.1319.979.927.650.054.81
Non-Operating Income (Expense)0.831.461.201.461.160.951.180.91
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.8011.074.145.277.645.014.443.60
Price To Earnings Ratio-120.92------
Price To Sales Ratio4.934.083.274.845.433.033.762.49
Gross Margin85.8883.4784.0284.0881.5779.5880.9779.72
Operating Margin15.785.629.5219.559.056.27-5.142.79
Net Margin10.53-33.772.6912.910.83-2.70-15.34-8.51
Shares Outstanding182.57173.59172.56166.22165.53161.22156.01149.43
Market Capitalization3,018.201,367.321,000.101,302.501,314.45747.92845.13505.38

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments111.0471.6272.45121.97102.43133.7975.55112.6342.05
Short Term Receivables51.0540.4139.2030.8317.466.885.642.871.20
Inventories68.6748.1738.8424.7318.128.352.180.000.00
Other Current Assets9.557.455.789.294.593.204.122.400.81
Total Current Assets240.31167.66156.26186.82142.60152.2187.48117.9044.05
Net Property, Plant & Equipment27.0628.2129.189.516.636.717.852.030.79
Total Investments and Advances4.024.124.224.350.000.0013.230.000.00
Intangible Assets110.94121.78132.62143.47154.31----
Deferred Tax Assets9.416.0918.200.120.36----
Other Assets1.201.280.320.380.830.230.420.100.16
Total Assets392.94329.15340.80344.64304.73159.15108.99120.0345.00
Short Term Debt Incl. Current Port. of LT Debt6.2321.183.501.580.000.000.000.000.00
Accounts Payable3.082.2911.564.618.923.125.600.871.98
Other Current Liabilities100.2776.9780.1367.4470.1225.0921.739.312.88
Total Current Liabilities109.57100.4495.1973.6279.0428.2127.3410.174.86
Long Term Debt251.87250.26225.70196.4888.0787.0258.3031.890.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities9.416.0920.463.635.31----
Other Liabilities8.401.976.2325.7237.0810.168.912.560.09
Total Liabilities379.25358.77347.58299.45209.49125.3994.5544.624.95
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.0097.88
Common Equity13.69-29.61-6.7845.1995.2333.7614.4475.41-57.83
Total Shareholders Equity13.69-29.61-6.7845.1995.2333.7614.4475.4140.05
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity13.69-29.61-6.7845.1995.2333.7614.4475.4140.05
Total Liabilities & Stockholders Equity392.94329.15340.80344.64304.73159.15108.99120.0345.00
Book Value Per Share0.08-0.20-0.050.330.760.570.533.62-2.81
Tangible Book Value Per Share-0.59-1.01-1.01-0.72-0.470.570.533.62-2.81
Full-Time Employees4353943773552941802029046
Price to Book Ratio61.82-17.8383.963.293.848.6913.294.693.70
Return on Assets0.15-16.37-18.17-29.15-52.91-67.98-109.67-72.81-67.63
Return on Equity---324.20-134.83-190.28-378.20-279.56-104.08-74.79
Return on Invested Capital0.21-24.85-28.44-39.17-66.95-75.46-172.64-55.99-66.31
Quick Ratio1.571.191.232.201.575.103.1211.599.06
Current Ratio2.191.671.642.541.805.403.2011.599.06

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-6.500.55-54.84-62.26-94.66-122.72-91.14-125.58-60.08
Depreciation12.8412.6912.6213.1612.671.881.471.080.32
Other Funds (Non Cash)65.6325.7416.328.4315.6813.4611.918.381.87
Funds from Operations71.9738.99-28.16-41.91-67.74-107.39-77.76-116.12-57.89
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.68-10.36-8.82-6.29-35.1511.85-2.8011.781.61
Cash from Operating Activities73.6528.63-36.98-48.21-102.89-95.53-80.56-104.35-56.28
Capital Expenditures-1.03-0.70-0.87-2.26-0.52-1.08-0.38-1.11-1.51
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.0038.470.000.000.00
Purchase or Sale of Investments0.000.005.75-3.7434.9860.58-27.03-1.28-66.75
Purchase of Investments0.000.00-34.48-43.740.00-43.02-101.77-102.47-68.85
Sale Or Maturity of Investments0.000.0040.2440.0034.98103.6074.75101.202.10
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-1.03-0.704.88-6.0034.4697.96-27.41-2.38-68.26
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-19.232.22-2.00-0.4330.3727.2562.3257.9193.54
Repurchase of Common Pref Stock-22.32-10.88-3.73-1.01-0.47-0.53-0.060.000.00
Sale of Common Pref Stock3.1013.101.730.5830.8427.7862.3857.9193.54
Proceedsfrom Stock Options-0.830.000.000.0030.0026.9561.5857.2393.32
Issuance or Reduction of Debt, Net-13.919.1738.170.0097.840.0064.1522.6234.67
Change in Long Term Debt-13.919.1738.170.0097.840.0064.1522.6234.67
Issuance of Long Term Debt9.179.1750.000.00141.340.0089.2457.6234.67
Reduction of Long Term Debt-23.070.00-11.830.00-43.500.00-25.09-35.000.00
Net Financing Active Other Cash Flow0.000.000.000.00-0.740.00-0.400.000.00
Other Financing Activities Uses0.000.000.000.00-0.740.00-0.400.000.00
Cash from Financing Activities-33.1411.3936.17-0.43127.4727.25126.0680.53128.21
Exchange Rate Effect---0.000.00-0.00-0.020.000.00
Net Change in Cash39.4839.324.07-54.6459.0429.6718.08-26.203.67
Free Cash Flow72.6227.93-37.85-50.47-103.42-96.62-80.94-105.45-57.79
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow25.0048.55-------
Deferred Taxes & Investment Tax Credit-0.00-2.27-1.25-1.420.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments131.08121.75111.75111.0491.6059.28
Short Term Receivables68.6058.1056.3051.0553.7553.05
Inventories76.9280.9374.2368.6767.4667.28
Other Current Assets12.6613.979.409.5511.215.96
Total Current Assets289.26274.76251.68240.31224.02185.58
Net Property, Plant & Equipment26.2226.6126.9827.0627.2127.69
Total Investments and Advances4.024.024.024.024.024.12
Intangible Assets102.81105.52108.23110.94113.65116.36
Deferred Tax Assets---9.41--
Other Assets0.911.001.101.201.300.94
Total Assets423.22411.90392.01392.94370.19334.69
Short Term Debt Incl. Current Port. of LT Debt6.3570.096.276.236.196.16
Accounts Payable8.049.3411.473.086.539.46
Other Current Liabilities120.09110.14100.86100.27103.4879.55
Total Current Liabilities134.48189.57118.59109.57116.2095.17
Long Term Debt219.72219.35252.28251.87251.46251.07
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---9.41--
Other Liabilities20.2412.728.138.403.397.75
Total Liabilities374.44421.64379.00379.25371.05353.99
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity48.78-9.7313.0113.69-0.86-19.30
Total Shareholders Equity48.78-9.7313.0113.69-0.86-19.30
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity48.78-9.7313.0113.69-0.86-19.30
Total Liabilities & Stockholders Equity423.22411.90392.01392.94370.19334.69
Book Value Per Share0.27-0.060.080.08-0.01-0.12
Tangible Book Value Per Share-0.30-0.66-0.55-0.59-0.69-0.84
Full-Time Employees---435--
Price to Book Ratio61.82105.0470.42-1,509.62-67.99-20.74
Return on Assets-1.64-4.603.390.15-4.52-9.60
Return on Equity-27.11-----
Return on Invested Capital4.20-14.840.844.170.25-0.83
Quick Ratio1.581.021.501.571.351.24
Current Ratio2.151.452.122.191.931.95

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income11.29-31.102.2311.080.62-1.93
Depreciation3.223.213.213.203.193.16
Other Funds (Non Cash)11.7142.765.036.148.495.83
Funds from Operations26.2214.8610.4720.4212.307.06
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital9.25-6.60-0.60-0.376.14-6.88
Cash from Operating Activities35.478.269.8720.0418.430.18
Capital Expenditures-0.16-0.21-0.33-0.33-0.07-0.28
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.16-0.21-0.33-0.33-0.07-0.28
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-2.901.94-8.84-9.4313.850.94
Repurchase of Common Pref Stock-3.58-0.19-17.02-1.54-0.48-0.86
Sale of Common Pref Stock0.682.138.18-7.8914.331.80
Proceedsfrom Stock Options0.000.000.00-0.830.000.83
Issuance or Reduction of Debt, Net-23.070.000.009.170.000.00
Change in Long Term Debt-23.070.000.009.170.000.00
Issuance of Long Term Debt0.000.000.009.170.000.00
Reduction of Long Term Debt-23.070.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-25.981.94-8.84-0.2713.850.94
Net Change in Cash9.3410.000.7119.4432.210.84
Free Cash Flow35.318.059.5419.7118.36-0.10
Price to Free Cash Flow25.0024.5921.6850.61144.94-

Revenue breakdown

Gvoke2024: 82.83M 2025: 94.11M
Keveyis2024: 49.53M 2025: 47.65M
Product, Other2025: 1.96M
Recorlev2024: 64.28M 2025: 139.28M
Royalty, Contract And Other2024: 6.43M 2025: 8.84M
United States2024: 203.07M 2025: 291.85M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.18%9.0M173.5M2.34M
2026-10-154.64%8.0M173.1M2.21M
2026-09-304.16%7.2M173.1M2.18M
2026-09-154.66%8.1M173.0M1.86M
2026-08-314.66%8.0M172.5M1.87M
2026-08-145.02%8.7M173.9M1.85M
2026-07-315.30%9.2M173.9M1.89M
2026-07-156.12%10.1M164.7M1.87M
2026-06-307.73%12.8M165.1M1.73M
2026-06-157.76%12.8M165.0M1.65M
2026-05-297.55%12.5M165.9M1.76M
2026-05-157.46%12.4M165.8M1.91M
2026-04-309.89%15.9M160.8M1.76M
2026-04-159.80%15.7M160.6M1.81M
2026-03-3110.25%16.4M160.1M2.03M
2026-03-1310.13%16.2M160.1M2.08M
2026-02-2710.63%17.0M160.1M2.04M
2026-02-1311.29%17.4M154.1M1.99M
2026-01-3011.04%17.0M153.9M2.41M
2026-01-1510.88%16.9M155.2M2.50M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5011.9015.409.2013.5161950.000.993-0.0180.000
call5.009.4013.204.5810.5381.000.000.988-0.0180.001
call6.008.4012.100.008.7570.000.000.986-0.0180.001
call7.506.9010.608.737.1103402.000.983-0.0180.001
call9.005.809.107.455.8361.001.000.978-0.0170.001
call10.004.408.206.225.2856361.000.937-0.0450.003
call11.003.407.204.704.62792.000.000.846-0.1220.006
call12.502.005.003.401.8632920.000.806-0.1110.007
call14.000.803.002.151.4621530.000.750-0.0970.008
call15.001.152.401.651.5502112.000.695-0.0850.009
call16.000.401.900.931.6083171.000.603-0.0770.010
call17.500.002.400.371.6041.004.000.479-0.1080.010
call19.000.000.100.302.7292.000.000.428-0.1420.010
call20.000.002.200.000.8950.000.000.098-0.0230.004
call21.000.002.200.001.0580.000.000.085-0.0240.004
call22.000.002.200.001.2070.000.000.077-0.0250.004
call23.000.002.200.001.3460.000.000.071-0.0270.003
call24.000.002.200.001.4750.000.000.066-0.0280.003
call25.000.001.000.001.5960.000.000.062-0.0280.003
call26.000.002.150.001.7110.000.000.058-0.0290.003
call27.000.002.150.001.8190.000.000.056-0.0300.003
call28.000.002.150.001.9210.000.000.053-0.0300.003
call29.000.000.450.002.0180.000.000.051-0.0310.003
put2.500.000.050.005.7250.000.00-0.007-0.0150.001
put5.000.002.150.053.9171.000.00-0.012-0.0170.001
put6.000.002.150.003.3540.000.00-0.014-0.0170.001
put7.500.002.150.052.6722140.00-0.017-0.0170.001
put9.000.000.050.042.02719.001.00-0.023-0.0160.001
put10.000.000.200.052.65272.000.00-0.101-0.0620.005
put11.000.002.151.003.5105.000.00-0.154-0.1210.006
put12.500.002.152.532.76910.000.00-0.194-0.1100.007
put14.000.002.250.802.0872.000.00-0.250-0.0960.008
put15.000.000.950.251.64424.000.00-0.305-0.0830.009
put16.000.051.000.001.2410.000.00-0.397-0.0760.010
put17.500.403.400.002.7640.000.00-0.521-0.1060.010
put19.000.854.700.003.0520.000.00-0.883-0.0180.005
put20.001.855.600.003.2290.000.00-0.902-0.0200.004
put21.002.806.600.003.4770.000.00-0.915-0.0220.004
put22.003.807.600.003.7030.000.00-0.923-0.0230.004
put23.004.808.600.003.9110.000.00-0.929-0.0240.003
put24.005.809.600.004.1040.000.00-0.934-0.0250.003
put25.006.8010.600.004.2840.000.00-0.938-0.0260.003
put26.007.8011.600.004.4520.000.00-0.942-0.0260.003
put27.008.8012.600.004.6110.000.00-0.944-0.0270.003
put28.009.8013.600.004.7600.000.00-0.947-0.0270.003
put29.0010.8014.600.004.9020.000.00-0.949-0.0280.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-064Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-05144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-043Initial statement of beneficial ownership of securities2026-11-02SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-148-KCurrent report2026-10-13SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-28144Filing for proposed sale of securities under Rule 144.SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-01SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-01SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-03SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100772.70K4
2026-1000344.95K3
2026-0900561.24K4
2026-0800296.29K3
2026-07001.24M4
2026-0600503.23K5
2026-0500103.81K1
2026-040099.86K1
2026-0300164.12K2
2026-0200124.15K1
2026-0100420.03K3
2025-12001.20M3
2025-1100296.70K2

Institutional holders

Manager% owned
BlackRock, Inc.8.41%
D. E. Shaw & Co., Inc.4.52%
VANGUARD CAPITAL MANAGEMENT LLC4.25%
STATE STREET CORP2.79%
GEODE CAPITAL MANAGEMENT, LLC2.51%
Nuveen, LLC2.27%
Rosalind Advisors, Inc.1.68%
Qube Research & Technologies Ltd1.68%
VANGUARD PORTFOLIO MANAGEMENT LLC1.52%
WELLINGTON MANAGEMENT GROUP LLP1.37%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.01%
iShares Russell 2000 ETF2.58%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
College Retirement Equities Fund - Total Global Stock Account1.13%
Fidelity Small Cap Index Fund1.08%
iShares Russell 2000 Growth ETF0.92%
Nuveen Quant Small Cap Equity Fund0.69%
VANGUARD RUSSELL 2000 INDEX FUND0.54%
First Trust Small Cap Growth AlphaDEX Fund0.51%
Fidelity Extended Market Index Fund0.47%

OakChart. XERS. Cached 15 minutes.